Welcome to our dedicated page for Skye Bioscience SEC filings (Ticker: SKYE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Skye Bioscience, Inc. (Nasdaq: SKYE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Skye is a Nevada corporation and clinical-stage biotechnology company focused on metabolic health, and its filings offer structured insight into its financial condition, clinical programs, and material corporate events.
Investors researching SKYE can use this page to review current and historical reports such as Form 8-K, where Skye has furnished press releases on topics including topline CBeyond™ Phase 2a data for nimacimab, financial results for specific reporting periods, and other corporate updates. These 8-K filings link clinical milestones—such as Phase 2a obesity trial readouts, extension study enrollment, and Phase 1b results in metabolic-associated steatotic liver disease—to the company’s formal disclosure record.
Through Stock Titan, Skye’s filings are updated in near real time as they appear on the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents, allowing users to quickly understand the context of complex clinical and financial information. This includes highlighting how Skye describes nimacimab’s development status, safety and efficacy data reported in furnished press releases, and the company’s stated plans for future clinical studies.
In addition to event-driven Form 8-Ks, users can locate Skye’s annual and quarterly reports, once available, to examine consolidated financial statements, research and development expenditures, and risk factor discussions related to its obesity and metabolic health programs. The filings page also provides a path to monitor any future ownership and insider transaction disclosures, such as Form 4 filings, when they are reported. Together, these documents form a detailed regulatory history that supports deeper analysis of SKYE as a clinical-stage biotech issuer.
Skye Bioscience director Deborah H. Charych received a stock option grant for 75,000 shares of Common Stock. The option has an exercise price of $0.6150 per share, expires on March 31, 2036, and was awarded at no cost as a compensation grant.
The stock option vests in equal monthly installments over a one-year period beginning March 31, 2026. Following this grant, Charych holds 75,000 stock options directly, giving her the right to buy an equivalent number of common shares if she chooses to exercise in the future.
Skye Bioscience director Paul A. Grayson received a grant of stock options for 75,000 shares of Common Stock. The options have an exercise price of $0.615 per share and expire on March 31, 2036. The award vests in equal monthly installments over one year beginning March 31, 2026, and represents his full reported option holdings from this filing.
Skye Bioscience director Andrew J. Schwab received a grant of stock options covering 75,000 shares of common stock at an exercise price of $0.615 per share. The options were awarded at no upfront cost, expire on March 31, 2036, and vest in equal monthly installments over one year beginning March 31, 2026. This filing reflects a compensation-related equity award rather than an open-market purchase or sale of shares.
Skye Bioscience Chief Operating Officer Diep Tuan Tu reported a board-approved, one-time repricing of several stock option awards effective March 31, 2026. Existing options with exercise prices between $2.89 and $14.56 per share were surrendered and replaced with new options for the same share amounts at a $0.615 exercise price, matching the closing price on the repricing date.
The grants include, among others, a 150,000-share option expiring on February 25, 2035 and additional options for 75,000, 22,021, 9,194, 8,000 and 7,080 shares at the same $0.615 exercise price. These options generally vest in equal monthly installments over four years from their original vesting start dates and become fully vested upon a change in control. The filing reflects compensation-related option adjustments, not open-market purchases or sales of common stock.
Skye Bioscience reported that Chief Executive Officer Punit Dhillon had several existing stock option grants repriced effective March 31, 2026. Options covering blocks such as 650,000 and 250,000 shares were canceled and replaced with new options for the same share amounts, now carrying a $0.615 per-share exercise price, which matches the closing stock price on the repricing date. According to the disclosure, all other terms of each stock option remain unchanged.
One grant is already fully vested, while others continue to vest in equal monthly installments over four-year periods tied to original grant dates in 2023 and 2024. Each of these options becomes fully vested if there is a change in control of the company. These are compensation-related derivative transactions only and do not involve any open-market purchases or sales of common shares.
Skye Bioscience, Inc. received a Nasdaq deficiency letter on March 17, 2026 because its common stock’s closing bid price has stayed below $1.00 per share for 30 consecutive business days, violating Nasdaq Listing Rule 5450(a)(1) for The Nasdaq Global Market.
The stock continues trading under the “SKYE” symbol, and Skye has 180 calendar days, until September 14, 2026, to regain compliance, including the option to complete any reverse stock split at least ten business days before that date. If the bid price closes at or above $1.00 for at least 10 consecutive business days before that deadline, Nasdaq staff will confirm compliance. Skye may qualify for a second 180-day period on The Nasdaq Capital Market if it meets other listing standards and commits to curing the deficiency, but there is no assurance it will regain or maintain compliance.
Skye Bioscience reported fourth quarter and full-year 2025 results and detailed progress in its obesity program for nimacimab. In a Phase 2a trial, nimacimab plus semaglutide delivered 22.3% weight loss at 52 weeks and an approximately 3% incremental benefit at 26 weeks versus semaglutide alone, with a placebo-like safety profile and no drug-related neuropsychiatric events. Off-treatment, the combination cohort regained 17.8% of lost weight over 13 weeks versus 37.3% for semaglutide alone, with more favorable body composition changes. Skye has initiated a CBeyond Expansion Study testing 400 mg and 600 mg IV nimacimab and expects topline data in Q4 2026. Cash, cash equivalents and short-term investments totaled $25.7 million as of December 31, 2025, and the company expects this to fund operations and key clinical milestones through Q4 2026, excluding Phase 2b trial and related manufacturing costs. Full-year 2025 R&D expenses were $42.4 million and G&A expenses were $15.8 million, leading to a net loss of $55.9 million compared with $26.6 million in 2024.
Skye Bioscience is a clinical-stage biotech focused on treating obesity, overweight and metabolic disorders by modulating G‑protein‑coupled receptors. Its lead antibody, nimacimab, is a peripherally restricted negative allosteric modulator of the CB1 receptor designed to avoid brain-related safety issues seen with earlier small-molecule CB1 drugs.
Preclinical models showed dose‑dependent weight loss with fat mass reduction and lean mass preservation, plus durable effects and synergy when combined with incretin therapies. In the CBeyond Phase 2a trial, nimacimab 200 mg weekly did not meet the primary endpoint as monotherapy but, combined with semaglutide, produced greater mean weight loss (−13.2% versus −10.25%) and improved waist circumference, body composition and reduced rebound weight gain, with a placebo‑like safety profile. Interim extension data suggest continued benefit through 52 weeks. Skye is running an IV expansion study, planning a potential Phase 2b combination trial, has a subcutaneous delivery collaboration with Halozyme’s ENHANZE technology, and reports a global IP portfolio with patents extending into the mid‑2030s and beyond.
Skye Bioscience announced that Chief Financial Officer Kaitlyn Arsenault will step down effective February 20, 2026 to pursue new professional opportunities and will continue as an advisor. Under a Separation and Release Agreement, she will receive a $450,000 cash severance, an additional $45,000 toward her 2026 annual bonus, reimbursement of up to $30,000 in legal fees, and a lump-sum payment of $41,172.48 equal to 12 months of COBRA premiums.
Certain outstanding equity awards will continue to vest during her advisory term, and unvested awards will fully vest if a Change in Control occurs within a year and before the advisory role ends. Vested stock options will remain exercisable until the later of February 20, 2027 or 90 days after the advisory term ends. The company states her departure is not due to any disagreement on financial reporting or company practices. In connection with this change, the Board appointed CEO Punit Dhillon as principal accounting officer, with his existing compensation and roles otherwise unchanged.
Skye Bioscience director receives stock option grant. Director Andrew J. Schwab was granted a stock option for 35,000 shares of Skye Bioscience, Inc. common stock on February 6, 2026. The option has an exercise price of $0.82 per share and was awarded at no cost to him.
The option vests in equal monthly installments over a one-year period beginning January 19, 2026, and is exercisable until February 6, 2036. Following this grant, Schwab holds 35,000 derivative securities directly in the form of this stock option.